Digestive Health Newsletter

Inflammatory Bowel Disease -- Separating Fact from Fiction

Jeffrey A. Tuvlin, MD

Volume 22, 
September 01, 2010

by Jeffrey A. Tuvlin, MD

Jeffrey Tuvlin Dr. Jeffrey A. Tuvlin is the founder of the gastroenterology group with The Physicians Group at Jewish Hospital and St. Mary's Health Care in Louisville, Kentucky. Dr. Tuvlin specializes in the treatment of Inflammatory Bowel Diseases and is a frequently invited speaker on all topics related to IBD. Dr. Tuvlin teaches at the University of Louisville and has served as an advisory Dean for medical students at the University of Louisville School of Medicine.



Table of Contents



Introduction

Thanks to the Internet, we now have 24-hour access to medical information from the comfort of our homes. This has made it easier and faster to find answers to health-related questions, which may be especially useful if you have a chronic illness like inflammatory bowel disease (IBD). But, keep in mind that a wise consumer of medical information must have a discerning eye. Of the thousands of Web sites providing health-related information, many are misleading or inaccurate. This newsletter will debunk some of the most common myths you may have heard about IBD. It will also walk you through how to evaluate medical information you find online and provide information about credible online resources.

Back to Top

IBD Myths

FICTION:   Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are the same thing.

FACTS:   It’s easy to confuse IBD and IBS, since they occur in the same part of the body (your gastrointestinal system) and often share similar symptoms, like pain and diarrhea. But there are significant differences. For example, a hallmark of IBD is chronic inflammation of the digestive tract that sometimes flares, whereas IBS is a functional disorder of the intestines that does not involve active inflammation. Keep in mind that, 30% to 40% of the time, a person may have both IBD and IBS, since once the bowel is inflamed for any reason, an irritable bowel may develop due to heightened sensitivity.

 

FICTION:   IBD is caused by stress.

FACTS:   No one knows exactly what causes IBD. There are a number of hypotheses (for example, immune system malfunction, environmental factors, genetics, infection), but stress is not one of them. Studies have shown that stress does not cause the inflammation associated with IBD, but it can exacerbate the symptoms of an inflamed digestive tract and increase IBD severity.

For more information, refer to the “What Causes Inflammatory Bowel Disease” newsletter.

 

FICTION:   IBD is all in your head.

FACTS:   IBD is not imaginary (diagnosis depends on the presence of inflammation in your gastrointestinal tract), nor is it caused by psychological problems. On the other hand, IBD can lead to anxiety or depression. These issues are often associated with any chronic illness and are not the nature of IBD itself.

 

FICTION:   There’s a cure for IBD.

FACTS:   Although some Web sites may tout a “miracle cure” for IBD, there is currently no scientifically proven cure, with the exception of colectomy (removal of the colon) for patients with ulcerative colitis. However, medications can help you control inflammation, manage your symptoms, and prevent damage caused by inflammation. You might be tempted to try herbal or “natural” remedies, but just because herbs are natural does not mean they are necessarily safe. Keep in mind that both herbs and dietary supplements are unregulated, so it is often difficult to know what they actually contain or if they provide any of the benefits they claim. Always be sure to let your doctor know if you decide to try an alternative approach.

For more information, refer to the “Mind Your Meds” newsletter.

 

FICTION:   I used to have 15 bowel movements per day, but now I have only 11, so I am in remission.

FACTS:   Many factors are used to determine whether or not you are in remission. These include your symptoms, the appearance of your intestinal lining, and blood tests. And remember that you are not in remission if you are still on steroids. You and your doctor will decide together if you are truly in remission.

 

FICTION:   You can stop taking IBD medication when in remission.

FACTS:   Studies show that staying on your medication, even when you are feeling well, decreases your risk of relapse, disease progression, and possibly colorectal cancer (if you have ulcerative colitis). The single best way to stay in remission is to stay on your medication.

For more information, refer to the “Mind Your Meds” newsletter.

 

FICTION:   People with IBD eventually require surgery.

FACTS:   Not all people with IBD need surgery, but it is a reality for many. You are more likely to need surgery if you have Crohn’s disease, than if you have ulcerative colitis.

For more information, refer to the “Inflammatory Bowel Disease and Colorectal Surgery” newsletter.

 

FICTION:   People with IBD eventually get colon cancer.

FACTS:   Even though IBD can increase your risk, most people with UC or CD never get colon cancer. The best prevention strategies are to schedule periodic colonoscopies with biopsies and to take your medication as prescribed.

For more information, refer to the “IBD and Cancer” newsletter.

 

FICTION:   I can’t take my IBD medication when I’m pregnant.

FACTS:   Most of the medications used to treat IBD are safe to take when you are pregnant or breast feeding, with the exception of some antibiotics, thalidomide, and methotrexate. Remember that a healthy mother is important for a healthy baby. It is almost always better to take medication and be well during pregnancy, than to stop taking medication and be sick. The best strategy is to discuss your options with your physician before you get pregnant.

 

FICTION:   If you have IBD, smoking cigarettes can help.

FACTS:   There is a connection between IBD and nicotine, however smoking has opposite effects on Crohn’s disease and ulcerative colitis. Smoking increases you risk of developing Crohn’s disease. Smoking can also increase your flare-ups, your need for surgery, and your need for immunosuppressive medication. On the other hand, some studies indicate that smoking may prevent the onset of ulcerative colitis. Even so, the risks of smoking – for example, cancer, emphysema, and heart disease -- far outweigh any possible benefit.

 

FICTION:   The [fill in the blank] diet will cure my IBD.

FACTS:   No specific diet has been found to treat or cure IBD in a significant number of patients. That said, when you are experiencing active inflammation, you might find it helpful to eat a bland diet consisting of mildly seasoned foods that are low in fat and fiber. And if you have lactose intolerance or sensitivity, you will want to avoid dairy products and other sources of lactose. You can also try taking lactase enzyme tablets before a meal or adding lactase enzyme drops to milk.

For more information, refer to the “IBD and Your Diet” newsletter.

 

FICTION:   Any other symptoms I develop, even those not affecting my gastrointestinal system, are due to my IBD.

FACTS:   While it’s true that IBD can cause symptoms like arthritis, skin conditions, eye inflammation, and bone loss, it’s important not to jump to conclusions. Be sure to always let you doctor know if you are experiencing such symptoms, so that he or she can help you confirm their underlying cause.

Back to Top

ABCs of Web Site Evaluation

Because the Web is largely unregulated, anyone with a computer and Internet access can publish anything online. A number of research studies evaluating the quality of online health-related information have found that its accuracy varies widely. So how can you stay informed, yet identify the difference between reliable and unreliable sources of information? The ABCs of Web site evaluation are a good place to start. Try asking yourself if the information you find seems:

  • Accurate?

    To determine if health-related information you find online is accurate, ask yourself the following questions:

    • Is the information supported by facts?
    • Is the information consistent with other sources?
    • Is the information based on scientific information (e.g., published research)?
    • Is the information current and recent enough to be useful?
    • Is the information likely to change?

    Remember that many Web pages are not reviewed and that there are no Internet standards to ensure accuracy. Watch for red flags like poor grammar, spelling errors, and absence of a publication date.

  • Biased?

    Even if the health-related information you find seems accurate, important details or information may be omitted. Ask yourself the following questions to help you identify bias:

    • Does the author reveal a hidden agenda or other biases?
    • Is the author using the Web site as a virtual “soapbox”?
    • Is the author’s purpose to educate, persuade, or sell?

    When you are on the lookout for bias, red flags may include sensationalist claims (for example, a “miracle” or “secret” cure), emotional hooks (e.g., large fonts, use of all upper case letters, and a lot of exclamation marks), and the presentation of one-sided information.

  • Credible?

    Because anyone can publish a Web page, it is important to evaluate the author’s expertise. Try asking yourself these questions:

    • Is he/she an expert on the subject?
    • What was his/her training?
    • What are his/her credentials and affiliations?

    It’s a red flag if you cannot find information about the author and his/her credentials.

Back to Top

Credible Sources of Online Information

According to a recent study,1 few Web sites provide high-quality information about IBD treatment options. The authors of the study explain that, depending on the search engine you use (for example, Google, Yahoo, or AOL), Web sites are listed in order according to a number of proprietary criteria, none of which include an independent assessment of quality. Neither higher ranking by a search engine or nonprofit status are indicative of higher quality information. According to the study, best bets for online information about inflammatory bowel disease include the following:

Back to Top

Conclusion

The Web can be a great place to learn about IBD or other specific diseases. Just don’t fall for the “if it’s on the Internet, it must be true” trap. Smart patients know how to find Web sites that are accurate, unbiased, and credible; to ignore information that seems questionable, and to always consult with their physician before acting on anything they read, online or elsewhere.

Back to Top


1 van der Marel S, Duijvestein M, Hardwick JC, van den Brink GR, Veenendaal R, Hommes DW, Fidder HH. Quality of Web-based Information on Inflammatory Bowel Disease. Inflamm Bowel Dis. 2009 Dec;15(12):1891-1896.

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

WB 10/04

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter